NP_001153682.1
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
74,304 Da
NCBI Official Full Name
calcium-binding mitochondrial carrier protein Aralar2 isoform 1
NCBI Official Synonym Full Names
solute carrier family 25 (aspartate/glutamate carrier), member 13
NCBI Protein Information
calcium-binding mitochondrial carrier protein Aralar2
UniProt Protein Name
Calcium-binding mitochondrial carrier protein Aralar2
UniProt Synonym Protein Names
Citrin; Mitochondrial aspartate glutamate carrier 2; Solute carrier family 25 member 13
UniProt Synonym Gene Names
UniProt Entry Name
CMC2_HUMAN
NCBI Summary for SLC25A13
This gene is a member of the mitochondrial carrier family. The encoded protein contains four EF-hand Ca(2+) binding motifs in the N-terminal domain, and localizes to mitochondria. The protein catalyzes the exchange of aspartate for glutamate and a proton across the inner mitochondrial membrane, and is stimulated by calcium on the external side of the inner mitochondrial membrane. Mutations in this gene result in citrullinemia, type II. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, May 2009]
UniProt Comments for SLC25A13
SLC25A13: Catalyzes the calcium-dependent exchange of cytoplasmic glutamate with mitochondrial aspartate across the mitochondrial inner membrane. May have a function in the urea cycle. Defects in SLC25A13 are the cause of citrullinemia type 2 (CTLN2). Citrullinemia belongs to the urea cycle disorders. It is an autosomal recessive disease characterized primarily by elevated serum and urine citrulline levels. Ammonia intoxication is another manifestation. CTLN2 is characterized by neuropsychiatric symptoms including abnormal behaviors, loss of memory, seizures and coma. Death can result from brain edema. Onset is sudden and usually between the ages of 20 and 50 years. Defects in SLC25A13 are the cause of neonatal intrahepatic cholestasis due to citrin deficiency (NICCD). NICCD is a form of citrullinemia type 2 with neonatal onset. NICCD is characterized by suppression of the bile flow, hepatic fibrosis, low birth weight, growth retardation, hypoproteinemia, variable liver dysfunction. NICCD is generally not severe and symptoms disappear by one year of age with an appropriate diet. Years or even decades later, however, some individuals develop the characteristic features of citrullinemia type 2 with neuropsychiatric symptoms. Belongs to the mitochondrial carrier family. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Transporter, SLC family; Mitochondrial; Membrane protein, integral; Transporter; Membrane protein, multi-pass
Chromosomal Location of Human Ortholog: 7q21.3
Cellular Component: integral to plasma membrane; mitochondrial inner membrane; mitochondrion
Molecular Function: calcium ion binding; L-aspartate transmembrane transporter activity; L-glutamate transmembrane transporter activity; structural constituent of ribosome; transporter activity
Biological Process: aspartate transport; ATP biosynthetic process; carbohydrate metabolic process; cellular respiration; gluconeogenesis; glucose metabolic process; L-glutamate transport; malate-aspartate shuttle; response to calcium ion; translation; transport
Disease: Citrullinemia, Type Ii, Adult-onset; Citrullinemia, Type Ii, Neonatal-onset
Research Articles on SLC25A13
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-SLC25A13 antibody
Pathways associated with anti-SLC25A13 antibody
Diseases associated with anti-SLC25A13 antibody
Organs/Tissues associated with anti-SLC25A13 antibody
|